文献速递淋巴瘤白血病

Venetoclax联合利妥昔单抗治疗复发CLL:MURANO III期研究4年结果及基因组复杂性和基因突变的影响

Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study.
PubMed 文献 · J Clin Oncol · 2020-09-28

MURANO III期研究4年随访显示,固定疗程Venetoclax联合利妥昔单抗(VenR)较苯达莫司汀联合利妥昔单抗(BR)显著提高复发/难治CLL患者的PFS和OS,且达到不可测MRD者疗效持久。VenR后进展接受伊布替尼挽救治疗应答率高,基因组复杂性和基因突变影响MRD状态和PFS。

要点

  • VenR组4年PFS率57.3% vs BR组4.6%,OS率85.3% vs 66.8%。
  • 联合治疗结束时uMRD与更优PFS相关,后续伊布替尼挽救治疗应答率高。
  • 基因组复杂性和BIRC3、BRAF、TP53等突变影响MRD和PFS。

核心结论

  • 固定疗程VenR的疗效优势持续存在,在达到uMRD的患者中尤为持久。
  • VenR后进展接受伊布替尼挽救治疗应答率高。
  • 基因突变和基因组复杂性影响MRD率和PFS。

研究设计与样本

  • MURANO III期随机对照研究,共纳入389例复发/难治CLL患者,VenR组194例,BR组195例。
  • VenR组接受2年Venetoclax(前6周期联合利妥昔单抗),BR组接受6周期BR。
  • 评估PFS、OS、外周血MRD状态、基因组复杂性(GC)和基因突变。

主要发现

  • VenR组4年PFS率57.3%,BR组4.6%(HR 0.19;95%CI 0.14-0.25)。
  • VenR组4年OS率85.3%,BR组66.8%(HR 0.41;95%CI 0.26-0.65)。
  • 联合治疗结束时uMRD者PFS优于低MRD阳性(HR 0.50)和高MRD阳性(HR 0.15)。
  • VenR组进展后首选伊布替尼治疗者(n=12)可评估10例,应答率100%;后续Venetoclax方案者(n=14)可评估11例,应答率55%。

关键数值与推荐

  • 无(原文未报告相关推荐条款)

临床怎么用

  • 复发/难治CLL可考虑固定疗程VenR,尤其追求uMRD以获持久疗效。
  • VenR后进展者可选用伊布替尼挽救治疗。
  • 治疗中需关注基因组复杂性和BIRC3、BRAF、TP53、NOTCH1、XPO1突变对MRD和PFS的影响。

局限性

  • 无(原文未报告相关局限性)

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: In previous analyses of the MURANO study, fixed-duration venetoclax plus rituximab (VenR) resulted in improved progression-free survival (PFS) compared with bendamustine plus rituximab (BR) in patients with relapsed or refractory chronic lymphocytic leukemia (CLL). At the 4-year follow-up, we report long-term outcomes, response to subsequent therapies, and the predictive value of molecular and genetic characteristics. PATIENTS AND METHODS: Patients with CLL were randomly assigned to 2 years of venetoclax (VenR for the first six cycles) or six cycles of BR. PFS, overall survival (OS), peripheral-blood minimal residual disease (MRD) status, genomic complexity (GC), and gene mutations were assessed. RESULTS: Of 389 patients, 194 were assigned to VenR and 195 to BR. Four-year PFS and OS rates were higher with VenR than BR, at 57.3% and 4.6% (hazard ratio [HR], 0.19; 95% CI, 0.14 to 0.25), and 85.3% and 66.8% (HR, 0.41; 95% CI, 0.26 to 0.65), respectively. Undetectable MRD (uMRD) at end of combination therapy (EOCT) was associated with superior PFS compared with low MRD positivity (HR, 0.50) and high MRD positivity (HR, 0.15). Patients in the VenR arm who received ibrutinib as their first therapy after progression (n = 12) had a reported response rate of 100% (10 of 10 evaluable patients); patients subsequently treated with a venetoclax-based regimen (n = 14) had a reported response rate of 55% (six of 11 evaluable patients). With VenR, the uMRD rate at end of treatment (EOT) was lower in patients with GC than in those without GC (P = .042); higher GC was associated with shorter PFS. Higher MRD positivity rates were seen with BIRC3 and BRAF mutations at EOCT and with TP53, NOTCH1, XPO1, and BRAF mutations at EOT. CONCLUSION: Efficacy benefits with fixed-duration VenR are sustained and particularly durable in patients who achieve uMRD. Salvage therapy with ibrutinib after VenR achieved high response rates. Genetic mutations and GC affected MRD rates and PFS.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Kater AP, Wu JQ, Kipps T, et al. Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study. J Clin Oncol. 2020. PMID: 32986498. doi:10.1200/JCO.20.00948

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。